1. Home
  2. ICCC vs PYPD Comparison

ICCC vs PYPD Comparison

Compare ICCC & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$9.92

Market Cap

75.8M

Sector

Health Care

ML Signal

HOLD

Logo PolyPid Ltd.

PYPD

PolyPid Ltd.

HOLD

Current Price

$4.85

Market Cap

85.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCC
PYPD
Founded
1982
2008
Country
United States
Israel
Employees
N/A
75
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.8M
85.1M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
ICCC
PYPD
Price
$9.92
$4.85
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$12.25
AVG Volume (30 Days)
26.9K
62.0K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
53.85
N/A
EPS
N/A
N/A
Revenue
$26,493,169.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
51.64
N/A
52 Week Low
$4.52
$2.44
52 Week High
$10.25
$5.12

Technical Indicators

Market Signals
Indicator
ICCC
PYPD
Relative Strength Index (RSI) 70.87 62.13
Support Level $5.85 $4.15
Resistance Level N/A $5.05
Average True Range (ATR) 0.49 0.23
MACD 0.11 0.04
Stochastic Oscillator 83.11 83.75

Price Performance

Historical Comparison
ICCC
PYPD

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

About PYPD PolyPid Ltd.

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Share on Social Networks: